Measles, Mumps, Rubella and Varicella Virus Vaccine
- Atc Codes:J07BD54
Table of contents
- Brand Names
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Special Considerations
Brand Names
Europe
Austria: Priorix Tetra, Proquad; Belgium: Priorix Tetra; Bulgaria: Proquad; Cyprus: Priorix Tetra, Proquad; Czech Republic: Priorix Tetra, Proquad; Estonia: Priorix Tetra, Proquad; Germany: Priorix Tetra, Proquad, Vammrix; Greece: Priorix-Tetra, Proquad; Hungary: Priorix Tetra, Proquad; Ireland: Priorix Tetra, Proquad; Italy: Priorix Tetra; Latvia: Priorix Tetra; Lithuania: Priorix-Tetra, Proquad; Luxembourg: Proquad; Malta: Priorix Tetra; Netherlands: Priorix Tetra, Proquad; Poland: Priorix Tetra, Proquad; Portugal: Priorix Tetra, Proquad; Romania: Priorix Tetra, Proquad; Slovakia: Priorix Tetra, Proquad; Slovenia: Priorix Tetra, Proquad; Sweden: Priorix Tetra, Proquad.
North America
Canada: Priorix Tetra; USA: Proquad.
Drug combinations
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Vaccines. Live Viral Vaccine. (ATC-Code: J07BD54).
Mechanism of action
Offers active immunity to disease caused by measles, mumps, rubella, and varicella-zoster virus.
Therapeutic use
Provides simultaneous active immunization against measles, mumps, rubella, and varicella.
Pregnancy and lactiation implications
Unknown whether vaccine can cause fetal harm or affect reproduction capacity (contracting natural measles during pregnancy can increase fetal risk). Should not be administered to pregnant females and pregnancy should be avoided for 3 months following vaccination. Following vaccination of mother, rubella virus may be transmitted to nursing infant via breast milk.
Unlabeled use
Contraindications
Hypersensitivity to measles, mumps, rubella, and/or varicella vaccines, or any component of the formulation. Anaphylactic reaction to neomycin. Individuals with blood dyscrasias, leukemia, lymphomas, or other malignant neoplasms affecting bone marrow or lymphatic systems. Those receiving immunosuppressive therapy (including high-dose systemic corticosteroids). Primary and acquired immunodeficiency states. Family history of congenital or hereditary immunodeficiency. Active untreated tuberculosis. Current febrile illness with fever >38.5 °C (>101.3 °F). Pregnancy.
Warnings and precautions
Anaphylactoid and/or hypersensitivity reactions might occur. Children 12-23 months of age have higher risk of developing febrile seizures with use of combination product. May be administered in mild acute illness (with or without fever). Use with caution in history of cerebral injury, seizures, or other conditions where stress due to fever should be avoided. Use with caution in thrombocytopenia and patients who develop thrombocytopenia after first dose (thrombocytopenia may worsen). Avoid use of salicylates for 6 weeks following vaccination (varicella may increase risk of Reye’s syndrome). Products may contain albumin, or gelatin. Vaccine contains trace amounts of chick embryo antigen. Manufactured with neomycin. Recent administration of blood or blood products may interfere with immune response.